Group B strep clinical trial results ‘huge’ for NanoLogix
Links shared publicly online about this topic.
- 88total visits
Group B strep clinical trial results ‘huge’ for NanoLogix
View full resource at medcitynews.com
Tags: Group B Strep, Strep Throat, Clinical Trial
Most Recently Shared on August 8, 2011 at 10:04 am By:
Group B strep clinical trial results ‘huge’ for NanoLogix http://bit.ly/nTL0Tr
Due This Week: Key Phase II-B Clinical Trial Results for Important Smoking Cessation Program - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: LOS ANGELES, CA-- - A recent article in the New York Times highlighted the 22nd Century Group and the firm's "very low nicotine" tobacco which represents a disruptive technology that could transform ...” View full resource at finance.yahoo.com
Most Recently Shared on December 19, 2011 at 8:39 pm By:
Due This Week: Key Phase II-B Clinical Trial Results for Important Smoking Cessation Program: LOS ANGELES, CA-- ... http://t.co/GDIwmsCx
Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.” View full resource at news-medical.net
Most Recently Shared on October 31, 2011 at 2:18 pm By:
Lung Cancer News: Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tu... http://t.co/djFEqt79
Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia
news-medical.net — “CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.” View full resource at news-medical.net
Most Recently Shared on June 13, 2011 at 7:13 pm By:
News-Medical.Net Oncology and Health News
Oncology News: Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymph... http://bit.ly/lBWVlJ
University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep
news-medical.net — “NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of the University of Perugia in Italy.” View full resource at news-medical.net
Most Recently Shared on June 7, 2011 at 11:22 am By:
Meningitis News: University of Perugia researcher to lead BioNanoFilter European clinical trial on Group B Strep... http://bit.ly/jrHKnW
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation : Nature : Nature Publishing Group
nature.com — “Recent data from early clinical trials in melanoma patients carrying mutations in the B-RAF gene have shown promising results with the B-RAF kinase inhibitor PLX4032; however, many patients eventually develop resistance to this treatment. Two papers now uncover possible mechanisms of resistance to PLX4032. One paper shows that upregulation of MAP3K8 (which encodes COT) can confer resistance of melanoma cells to B-RAF inhibitors, whereas another paper found that melanomas can acquire resistance d” View full resource at nature.com
Most Recently Shared on November 24, 2010 at 11:44 pm By:
Eric D Whitman, MD Oncologist, Physician, Doctor, and Surgeon
2nd ltr in Nature re #melanoma BRAF resistance also identifies MAPK bypass mechanism through MEK. http://bit.ly/eV7w9v
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation : Nature : Nature Publishing Group
nature.com — “Recent data from early clinical trials in melanoma patients carrying mutations in the B-RAF gene have shown promising results with the B-RAF kinase inhibitor PLX4032; however, many patients eventually develop resistance to this treatment. Two papers now uncover possible mechanisms of resistance to PLX4032. One paper shows that upregulation of MAP3K8 (which encodes COT) can confer resistance of melanoma cells to B-RAF inhibitors, whereas another paper found that melanomas can acquire resistance d” View full resource at nature.com
Most Recently Shared on November 24, 2010 at 11:33 pm By:
Eric D Whitman, MD Oncologist, Physician, Doctor, and Surgeon
Nature article on acquired resistance to PLX-4032, NOT from BRAF mutation. http://bit.ly/hDhwhn
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma : Nature : Nature Publishing Group
nature.com — “PLX4032 is a selective inhibitor of the B-RAF protein that has shown promising results in an early clinical trial in melanoma patients with an activating mutation in B-RAF. Now the structure and function of this inhibitor are described. Translational data from a phase I trial show that clinical efficacy requires a substantial degree of inhibition of the ERK pathway downstream of B-RAF. The data also show that BRAF-mutant melanomas are highly dependent on B-RAF activity.” View full resource at nature.com
Most Recently Shared on October 25, 2010 at 4:14 am By:
Research Library: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma: (Sourc... http://bit.ly/bb9Bf2
Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
physorg.com — “The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.” View full resource at physorg.com
Most Recently Shared on October 12, 2010 at 4:45 pm By:
Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors http://bit.ly/bAaEHV
Promising Results in Heart Valve Clinical Trial - NYTimes.com
nytimes.com — “Survival rates rose for those receiving the valve, though the incidence of strokes and other complications was higher for that group.” View full resource at nytimes.com
Most Recently Shared on September 22, 2010 at 10:56 pm By:
Promising Results in Heart Valve Trial http://nyti.ms/bMiYWN
Queen’s Prostate Cancer Study Reveals Best Treatment | Kingston Herald
kingstonherald.com — “A new NCIC Clinical Trials Group study conducted at Queen's University reveals that combining radiation and hormone therapy in patients with high risk prostate cancer significantly improves the likelihood of patients living longer. Wendy Parulekar, an associate professor of oncology at Queen's and a Physician Coordinator at the NCIC CTG, described the results as having a [...]” View full resource at kingstonherald.com
Most Recently Shared on June 8, 2010 at 6:15 am By:
Queen's Prostate Cancer Study Reveals Best Treatment http://bit.ly/b5TKyZ
Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting
news-medical.net — “Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).” View full resource at news-medical.net
Most Recently Shared on April 20, 2010 at 3:18 pm By:
Medicare News: Teva Pharmaceutical Industries presents ADAGIO study results at AAN Annual Meeting: Teva Pharmaceut... http://bit.ly/bVyrbL
Lundbeck says stroke drug positive in phase-3 test | Reuters
reuters.com — “COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck said on Thursday a new analysis of a clinical phase III trial with its candidate stroke drug Desmoteplase showed positive results. The re-analysis” View full resource at reuters.com
Most Recently Shared on February 25, 2010 at 10:41 am By:
Lundbeck says stroke drug positive in phase-3 test: COPENHAGEN (Reuters) - Danish pharmaceutical grou... http://bit.ly/bPmF71 #health #news
Advertisement
